Author: Buttari, Fabio; Bruno, Antonio; Dolcetti, Ettore; Azzolini, Federica; Bellantonio, Paolo; Centonze, Diego; Fantozzi, Roberta
Title: COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab Cord-id: b8cunusp Document date: 2021_5_4
ID: b8cunusp
Snippet: Since the recent approval of vaccines against COVID-19, efficacy concerns emerged for MS patients treated with immunosuppressive drugs. We report our experience in four patients, under cladribine (two) or under ocrelizumab (two) treatment, all with low lymphocyte count, three of them vaccinated after 3 months from the last dose with good immune response, one (under ocrelizumab) after 2 months, without developing an appropriate title of antibodies. This experience suggests that the discriminant f
Document: Since the recent approval of vaccines against COVID-19, efficacy concerns emerged for MS patients treated with immunosuppressive drugs. We report our experience in four patients, under cladribine (two) or under ocrelizumab (two) treatment, all with low lymphocyte count, three of them vaccinated after 3 months from the last dose with good immune response, one (under ocrelizumab) after 2 months, without developing an appropriate title of antibodies. This experience suggests that the discriminant for the response to the vaccine is not the lymphocyte count but the timing of the vaccination.
Search related documents:
Co phrase search for related documents- absolute count and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- absolute value and lymphocyte absolute count: 1, 2, 3, 4, 5, 6, 7, 8
- absolute value and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9
Co phrase search for related documents, hyperlinks ordered by date